Results 91 to 100 of about 265 (150)

Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. [PDF]

Antimicrob Agents Chemother, 1994
Mizukane R, Hirakata Y, Kaku M, Ishii Y, Furuya N, Ishida K, Koga H, Kohno S, Yamaguchi K.   +8 more
europepmc   +1 more source

Radioimmunoassay for metabolites of 9,3"-diacetylmidecamycin, a macrolide antibiotic. [PDF]

Antimicrob Agents Chemother, 1982
Shimada N, Ueda T, Yokoshima T, Umemura K, Shomura T.   +4 more
europepmc   +1 more source

Antibiotic resistance in Helicobacter pylori [PDF]

, 2003
Chatsuwan, Tanittha
core  

Some of the next articles are maybe not open access.

Related searches:

Effect of miocamycin on theophylline kinetics in children

European Journal of Clinical Pharmacology, 1987
The interaction between a new macrolide antibiotic, miocamycin, and theophylline was evaluated in a single cross-over study in 5 asthmatic children. Each patient received a single dose of theophylline (4.3 mg/kg) delivered in 15 min using a constant-rate infusion pump, immediately before and after a 10 day course of miocamycin 17.5 mg/kg b.d.
N, Principi, J, Onorato, M G, Giuliani, A, Vigano   +3 more
exaly   +3 more sources

Effects of Miocamycin and Erythromycin on Polymorphonuclear Cell Function

Journal of Chemotherapy, 1992
Previous studies have shown that erythromycin can enter phagocytic cells, stimulating their functional activity. In this work we compared the effects of erythromycin and another newer macrolide antibiotic, miocamycin, on a series of in vitro tests aimed at evaluating their influence on polymorphonuclear cell (PMN) functions.
P. Bacci, A. Grossi, VANNUCCHI, ALESSANDRO MARIA, D. Rafanelli, A. Casini, M. De Luca   +5 more
exaly   +4 more sources

Pharmacokinetics of Miocamycin Following Intravenous Administration to Cattle

Transboundary and Emerging Diseases, 2000
The plasma pharmacokinetics for a single intravenous dose (10 mg/kg body weight) of miocamycin (a 16‐membered macrolide drug) was investigated in Holando Argentino cattle (n = 5). Blood drug concentrations were determined by a microbiological method and data were best‐fitted to a two‐compartment open model.
N J, Litterio, M R, Rubio, E A, Formentini, D C, Díaz, E J, Picco, T, Encinas, J C, Boggio   +6 more
exaly   +3 more sources

Kinetic Profile of Miocamycin in Middle Ear Fluid and Mucosa

Acta Oto-Laryngologica, 1991
A group of 18 patients, before undergoing otoplastic surgery, was treated with miocamycin 600 mg in a single dose; middle ear tissue samples were collected at 2, 3, 4 and 6 h. A group of 20 patients suffering from secretory otitis media (SOM) was also treated with 600 mg of miocamycin in a single dose; collections of middle ear fluid (MEF) were ...
Francesco Scaglione
exaly   +3 more sources

Miocamycin Distribution in Tonsillar and Pulmonary Tissues after Repeated Administration

Journal of Chemotherapy, 1990
Twenty patients undergoing tonsillectomy were treated with a peroral administration of 600 mg of miocamycin every 12 hours for 4 days. On the 5th day, after a last administration of a dose of 600 mg the ablation of the tonsils was carried out on groups of 4 subjects, each one at the following times after oral intake of the drug: 2, 4, 6, 8, 12 h ...
Francesco Scaglione
exaly   +3 more sources

Post-antibiotic effects of miocamycin, roxithromycin and erythromycin on Gram-positive cocci

International Journal of Antimicrobial Agents, 1993
The 16-membered macrolide miocamycin (MOM) has been compared with the 14-membered compounds erythromycin and roxithromycin in terms of causing post-antibiotic effects (PAE). Five strains of methicillin-resistant Staphylococcus aureus, 3 Streptococcus pyogenes, 3 S.
J M, Hamilton-Miller, S, Shah
exaly   +3 more sources

Midecamycin and miocamycin

2016
exaly   +2 more sources